1			CUSTOMER NUMBER 25268
2	IN THE UNITED STATES PATENT AND TRADEMARK OFFICE		
3	Applicants:	Call et al.	Attorney Docket No. MESO0070
4			·
5	Serial No.:	10/791,189	Group Art Unit: 1743
6	Filed:	March 1, 2004	Examiner: Douglas, Katherine L.
7			Confirmation No. 3193
8 9	Title:	BIOLOGICAL AL	ARM
10			FOR ELECTRONIC FILING
11		<u>SUPPLEMENTAL</u>	INFORMATION DISCLOSURE STATEMENT
12	Bellevue, Washington 98004		
13			December 19, 2006
14 15	TO THE COMMISSIONER FOR PATENTS:		
16	Applicant is aware of the information listed in the attached form that may be material to the		
17	prosecution of the above-identified patent application.		
18 19	1.	Copies of the listed F the Examiner's use.	oreign Patent Documents and Other Information are submitted for
20	2.	or submitted to the	utents, publications, and other information were previously cited by U.S. Patent and Trademark Office in prior application Serial, and relied upon for an earlier filing date under 35 U.S.C. § 120.
22 23 24	3.	application relied upo	in marked with an "**" have not previously been cited in a priority in herein for an earlier filing date. Copies of any so-noted Foreign Other Information are submitted for the Examiner's use.
25 26 27	4.	the English language	on of the relevance of document I.D. No (which is not in a), as presently understood by the individual designated under 37 t knowledgeable about its content, is provided
28 29 30	<u>X</u> 5.	within three months of the date of entry of the	R. § 1.97(b), this information disclosure statement is being filed of the filing date of the national application, within three months of e national stage as set forth in 37 C.F.R. § 1.491 in an international the mailing date of a first Office Action on the merits.
31	6.	Submission with RC	EE: Pursuant to 37 C.F.R. § 1.114, this information disclosure

1 2		statement is being submitted concurrently with a Request for Continued Examination (RCE) in the above-identified application.		
3 4 5	7.	Pursuant to 37 C.F.R. § 1.97(c), this information disclosure statement is being filed after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, and is accompanied by:		
6	a.	a certification as specified in 37 C.F.R. § 1.97(e) (see below); or		
7	b.	the fee set forth in 37 C.F.R. § 1.17(p). Fees in the amount of \$ will be charged to a credit card during electronic submission.		
8 9	8.	Pursuant to 37 C.F.R. § 1.97(d), this information disclosure statement is being filed after the mailing date of either:		
10	a.	a final action under 37 C.F.R. § 1.113; or		
12	b.	a notice of allowance under 37 C.F.R. § 1.311,		
13		but before payment of the issue fee. The statement is accompanied by a		
14		certification as specified in 37 C.F.R. § 1.97(e), a statement requesting		
15		consideration of the information disclosure statement, and the petition fee set forth in 37 C.F.R. § 1.17(p). Fees in the amount of \$ will be		
16		charged to a credit card during electronic submission.		
17	<u>X</u> 9.	Electronic Filing Authorization to Charge Deposit Account: Please charge any additional fees or credit any overpayment to Deposit Account No. 01-1940.		
18		additional rees of eredit any overpayment to Deposit Account No. 01 1540.		
19				
20		Respectfully submitted,		
21				
22				
23		/mike king/		
24		Michael C. King		
25		Registration No. 44,832		
26				
27				
28				
29				
30				
31				